



Attorney Docket No.: 6116.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Keith Anderson et al.

Application No.: 09/757,788

Group Art Unit: 1654

Filed: January 10, 2001

Examiner: Teller, Roy R

For: Transepithelial Delivery Of GLP-1 Derivatives

Confirmation No. 8259

#18
H-Q-1
7/12/03
RECEIVED

JUN 25 2003

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement mailed May 19, 2003, Applicants elect the claims of group I, claims 1-8, drawn to peptides having the amino acid sequence of SEQ ID NO: 1 (ie the GLP-1 of formula II on pages 7-8 of the application), for continued prosecution and select the following species:

Arg34-GLP-1(7-37)-OH; the spacer gamma-GLU and Arg34Lys26(N-gamma-glutamyl(N-hexadecanoyl))) -GLP-1(7-37)-OH.

Respectfully submitted,

Date: June 19, 2003

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800



23650

PATENT TRADEMARK OFFICE